IL221575A - Cells for supply of angiogenesis - Google Patents

Cells for supply of angiogenesis

Info

Publication number
IL221575A
IL221575A IL221575A IL22157512A IL221575A IL 221575 A IL221575 A IL 221575A IL 221575 A IL221575 A IL 221575A IL 22157512 A IL22157512 A IL 22157512A IL 221575 A IL221575 A IL 221575A
Authority
IL
Israel
Prior art keywords
cells
providing angiogenesis
angiogenesis
providing
Prior art date
Application number
IL221575A
Other languages
English (en)
Hebrew (he)
Original Assignee
Abt Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abt Holding Co filed Critical Abt Holding Co
Publication of IL221575A publication Critical patent/IL221575A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/02—Compounds of the arachidonic acid pathway, e.g. prostaglandins, leukotrienes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
IL221575A 2010-02-25 2012-08-22 Cells for supply of angiogenesis IL221575A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30810310P 2010-02-25 2010-02-25
PCT/US2011/025846 WO2011106365A1 (en) 2010-02-25 2011-02-23 Modulation of angiogenesis

Publications (1)

Publication Number Publication Date
IL221575A true IL221575A (en) 2017-12-31

Family

ID=44507175

Family Applications (3)

Application Number Title Priority Date Filing Date
IL221575A IL221575A (en) 2010-02-25 2012-08-22 Cells for supply of angiogenesis
IL255914A IL255914B (en) 2010-02-25 2017-11-26 A method that includes testing cells for the expression and/or secretion of one or more pro-angiogenic factors
IL270957A IL270957B2 (en) 2010-02-25 2019-11-26 Modulation of angiogenesis

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL255914A IL255914B (en) 2010-02-25 2017-11-26 A method that includes testing cells for the expression and/or secretion of one or more pro-angiogenic factors
IL270957A IL270957B2 (en) 2010-02-25 2019-11-26 Modulation of angiogenesis

Country Status (12)

Country Link
EP (1) EP2539439B1 (enExample)
JP (7) JP2013520509A (enExample)
KR (1) KR101900507B1 (enExample)
CN (1) CN102858956B (enExample)
AU (1) AU2011220940C1 (enExample)
BR (1) BR112012021451B8 (enExample)
CA (1) CA2791331A1 (enExample)
DK (1) DK2539439T3 (enExample)
ES (1) ES2703428T3 (enExample)
IL (3) IL221575A (enExample)
SG (4) SG10201501353YA (enExample)
WO (1) WO2011106365A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913920PA (en) 2010-05-12 2020-03-30 Abt Holding Co Modulation of splenocytes in cell therapy
EP3533465A4 (en) * 2016-09-26 2020-07-01 MPO, Inc. Egg, fertilized egg, or embryo quality improving agent
KR102656200B1 (ko) * 2017-06-16 2024-04-12 아이엠비에이 - 인스티튜트 퓌어 몰레쿨라레 바이오테크놀로지 게엠베하 혈관 오가노이드, 상기 오가노이드의 제조 및 사용 방법
DE102017116204B4 (de) * 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration
KR102498202B1 (ko) * 2019-01-24 2023-02-10 가톨릭대학교 산학협력단 줄기세포의 혈관 재생 유효성 평가 방법

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4304907A (en) * 1972-05-10 1981-12-08 The Upjohn Company Bicyclo lactone intermediates for prostaglandin analogs
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
EP0435928A1 (en) 1988-09-21 1991-07-10 Animal Biotechnology Cambridge Limited Derivation of pluripotential embryonic cell lines from domestic animals
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US7037721B1 (en) 1990-01-29 2006-05-02 Hy-Gene Biomedical, Inc. Protein-free defined media for the growth of normal human keratinocytes
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
AU2882992A (en) 1991-11-06 1993-06-07 Arthur A. Axelrad Cell culture medium
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US5340740A (en) 1992-05-15 1994-08-23 North Carolina State University Method of producing an avian embryonic stem cell culture and the avian embryonic stem cell culture produced by the process
US5453357A (en) 1992-10-08 1995-09-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US7153684B1 (en) 1992-10-08 2006-12-26 Vanderbilt University Pluripotential embryonic stem cells and methods of making same
US5766951A (en) 1992-11-12 1998-06-16 Quality Biological, Inc. Serum-free medium supporting growth and proliferation of normal bone marrow cells
CA2169292C (en) 1993-08-12 2010-11-23 E. Edward Baetge Improved compositions and methods for the delivery of biologically active molecules using genetically altered cells contained in biocompatible immunoisolatory capsules
US6037174A (en) 1993-08-23 2000-03-14 Nexell Therapeutics, Inc. Preparation of serum-free suspensions of human hematopoietic cells or precursor cells
US5409813A (en) 1993-09-30 1995-04-25 Systemix, Inc. Method for mammalian cell separation from a mixture of cell populations
US6432711B1 (en) 1993-11-03 2002-08-13 Diacrin, Inc. Embryonic stem cells capable of differentiating into desired cell lines
FR2726003B1 (fr) 1994-10-21 2002-10-18 Agronomique Inst Nat Rech Milieu de culture de cellules embryonnaires totipotentes aviaires, procede de culture de ces cellules, et cellules embryonnaires totipotentes aviaires
US5914268A (en) 1994-11-21 1999-06-22 National Jewish Center For Immunology & Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5874301A (en) 1994-11-21 1999-02-23 National Jewish Center For Immunology And Respiratory Medicine Embryonic cell populations and methods to isolate such populations
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US5908782A (en) 1995-06-05 1999-06-01 Osiris Therapeutics, Inc. Chemically defined medium for human mesenchymal stem cells
US6190910B1 (en) 1996-05-21 2001-02-20 The Institute Of Physical And Chemical Research Mouse embryonic stem cell lines
US5945337A (en) 1996-10-18 1999-08-31 Quality Biological, Inc. Method for culturing CD34+ cells in a serum-free medium
AU7984498A (en) 1997-06-25 1999-01-04 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Serum-free cell growth medium
EP1129176A4 (en) 1998-11-09 2002-10-30 Es Cell Int Pte Ltd EMBRYONIC STEM CELLS
CA2348687A1 (en) 1998-11-09 2000-05-18 Consorzio Per La Gestione Del Centro Di Biotecnologie Avanzate Serum free medium for chondrocyte-like cells
US8609412B2 (en) * 1999-08-05 2013-12-17 Regents Of The University Of Minnesota Mapc generation of lung tissue
US8075881B2 (en) * 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
DK1226233T3 (da) * 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US7015037B1 (en) * 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US20060003323A1 (en) * 2000-03-01 2006-01-05 John Alsobrook Therapeutic polypeptides, nucleic acids encoding same, and methods of use
JP4795616B2 (ja) 2000-06-20 2011-10-19 イーエス・セル・インターナショナル・プライヴェート・リミテッド Ｂｍｐ−２経路アンタゴニストの存在下においてｅｓ細胞を培養することによって胚性幹細胞の分化をコントロールする方法
US8071740B2 (en) * 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
CA2438501C (en) 2001-02-14 2014-09-16 Leo T. Furcht Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
EP1421181A1 (en) 2001-08-23 2004-05-26 Reliance Life Sciences Pvt., Ltd. ISOLATION OF INNER CELL MASS FOR THE ESTABLISHMENT OF HUMAN EMBRYONIC STEM CELL (hESC) LINES
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
US6703279B2 (en) 2002-01-04 2004-03-09 Promos Technologies, Inc. Semiconductor device having contact of Si-Ge combined with cobalt silicide
WO2003064598A2 (en) 2002-01-25 2003-08-07 Genzyme Corporation Serum-free media for chondrocytes and methods of use thereof
US7145057B2 (en) 2002-02-01 2006-12-05 Origen Therapeutics, Inc. Chimeric bird from embryonic stem cells
AU2003222252A1 (en) * 2002-03-12 2003-09-29 The General Hospital Corporation Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
GB0221481D0 (en) 2002-09-16 2002-10-23 Richards John M Grip for hand held instruments
WO2004039248A2 (en) * 2002-10-31 2004-05-13 The General Hospital Corporation Repairing or replacing tissues or organs
JP2005065661A (ja) * 2003-08-20 2005-03-17 Akihiro Yamaguchi ヒト血管内皮細胞のＶＥＧＦ誘導性活性化及び血管新生におけるＩｄの役割
FR2893252B1 (fr) * 2005-11-17 2008-02-15 Engelhard Lyon Sa Extraits vegetaux stimulant has2
US11992507B2 (en) * 2006-01-23 2024-05-28 Abt Holding Company MAPC therapeutics without adjunctive immunosuppressive treatment
US20070253937A1 (en) * 2006-04-26 2007-11-01 Young-Sup Yoon Novel multipotent stem cells and use thereof
US20100239535A1 (en) * 2006-05-17 2010-09-23 University Of Basel Method for isolating homogeneous populations of transduced progenitors stably expressing specific levels of a transgene
US20090053182A1 (en) * 2007-05-25 2009-02-26 Medistem Laboratories, Inc. Endometrial stem cells and methods of making and using same
AU2010276201B2 (en) * 2009-07-21 2013-10-17 Healios K.K. Use of stem cells to reduce leukocyte extravasation

Also Published As

Publication number Publication date
BR112012021451A2 (pt) 2015-09-15
AU2011220940B2 (en) 2014-10-02
JP2015109866A (ja) 2015-06-18
CN102858956B (zh) 2015-08-26
BR112012021451B8 (pt) 2021-05-25
DK2539439T3 (en) 2019-01-28
KR20130001249A (ko) 2013-01-03
WO2011106365A1 (en) 2011-09-01
JP2023026662A (ja) 2023-02-24
CA2791331A1 (en) 2011-09-01
EP2539439B1 (en) 2018-10-17
CN102858956A (zh) 2013-01-02
IL255914B (en) 2019-12-31
EP2539439A4 (en) 2013-09-04
SG183498A1 (en) 2012-09-27
IL270957B (en) 2022-12-01
IL270957B2 (en) 2023-04-01
JP6312326B2 (ja) 2018-04-18
BR112012021451B1 (pt) 2021-04-13
AU2011220940A1 (en) 2012-09-20
JP2021058218A (ja) 2021-04-15
IL270957A (en) 2020-01-30
IL255914A (en) 2018-01-31
JP2019089846A (ja) 2019-06-13
JP2015214585A (ja) 2015-12-03
SG10201501353YA (en) 2015-04-29
JP2017137355A (ja) 2017-08-10
EP2539439A1 (en) 2013-01-02
KR101900507B1 (ko) 2018-09-19
JP2013520509A (ja) 2013-06-06
AU2011220940C1 (en) 2015-04-16
SG10202102952YA (en) 2021-05-28
ES2703428T3 (es) 2019-03-08
SG10201913904PA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
IL250234B (en) Creating blood vessels using placental stem cells
AP3107A (en) 5-Alkynyl-pyrimidines
GB201013639D0 (en) Cell selection
GB2497058B (en) Separator
GB201205984D0 (en) No details
GB201112400D0 (en) No details
GB201017421D0 (en) Cell
GB2485334B (en) Structure
GB201009998D0 (en) Cell disruption
GB2486173B (en) Separator
GB201018480D0 (en) Factors
IL221575A (en) Cells for supply of angiogenesis
IL204981A0 (en) Collet
EP2591985A4 (en) PANEL ASSEMBLY STRUCTURE
GB201019024D0 (en) Improved reformer
GB201109038D0 (en) Lead
GB201202348D0 (en) No details
GB201105908D0 (en) No details
GB201014672D0 (en) Photovoltaics
GB201020580D0 (en) Cells
GB201019304D0 (en) Cells
EP2598166A4 (en) CELLS WITHOUT CMH
GB201019108D0 (en) Cell
TWM385388U (en) Card-peeking structure
TWM403148U (en) Wire-collecting structure

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed